DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

September 21, 2022

https://www.globenewswire.com/news-release/2022/09/21/2520644/0/en/DBV-Technologies-Provides-Clinical-Update-on-VITESSE-Phase-3-Trial.html

Montrouge, France, September 21, 2022

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

DBV Technologies (Euronext:DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical study.

Read more at globenewswire.com

Related news for (DBVT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.